The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! About 2.09 million shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 217.92% since April 27, 2016 and is uptrending. It has outperformed by 212.70% the S&P500.
The move comes after 5 months negative chart setup for the $1.89 billion company. It was reported on Nov, 30 by Barchart.com. We have $32.57 PT which if reached, will make NASDAQ:SRPT worth $94.50 million less.
Analysts await Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings on February, 23. They expect $-1.24 earnings per share, up 13.89% or $0.20 from last year’s $-1.44 per share. After $-1.10 actual earnings per share reported by Sarepta Therapeutics Inc for the previous quarter, Wall Street now forecasts 12.73% negative EPS growth.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was initiated by Janney Capital with “Neutral” on Wednesday, April 20. PiperJaffray upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) on Monday, September 19 to “Overweight” rating. The firm has “Buy” rating by Needham given on Friday, July 22. As per Wednesday, August 26, the company rating was maintained by TH Capital. The rating was downgraded by SunTrust to “Reduce” on Tuesday, April 26. The rating was downgraded by William Blair to “Market Perform” on Thursday, April 21. The rating was downgraded by RBC Capital Markets to “Sector Perform” on Tuesday, January 19. William Blair upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Monday, September 19. William Blair has “Outperform” rating and $88 price target. The company was upgraded on Monday, September 19 by Janney Capital. On Wednesday, August 26 the stock rating was maintained by Roth Capital with “Buy”.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.52 in 2016 Q2. Its up 0.36, from 1.16 in 2016Q1. The ratio increased, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Capital Fincl Advisers Ltd Liability accumulated 0.01% or 30,044 shares. The New Jersey-based Jacobs Levy Equity Incorporated has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Eagle Asset Mgmt Incorporated accumulated 0.05% or 354,290 shares. Fred Alger Mgmt Incorporated has 0.01% invested in the company for 70,000 shares. Moreover, Schwab Charles Management has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 153,816 shares. Nationwide Fund Advsrs accumulated 28,047 shares or 0% of the stock. Quinn Opportunity Ptnrs Ltd Llc last reported 17,500 shares in the company. First Midwest National Bank & Trust Trust Division has invested 0.08% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Natl Planning Corp accumulated 16,053 shares or 0.03% of the stock. Emerald Advisers Incorporated Pa last reported 235,506 shares in the company. Mizuho Usa last reported 174,400 shares in the company. Citigroup holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 32,489 shares. Moreover, Employees Retirement Association Of Colorado has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 12,338 shares. One Trading Lp has 0.13% invested in the company for 571,145 shares. Great West Life Assurance Can holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 4,935 shares.
Insider Transactions: Since September 14, 2016, the stock had 0 buys, and 8 selling transactions for $8.94 million net activity. The insider Howton David T sold 9,304 shares worth $465,200. Another trade for 40,179 shares valued at $2.41 million was made by Kaye Edward M. MD on Thursday, September 22. Another trade for 7,311 shares valued at $438,660 was sold by Ruff Shamim. The insider Mahatme Sandesh sold $1.50M. $1.75 million worth of shares were sold by Aphale Jayant on Monday, September 19.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.